Chimeric antigen receptor T-cell (or CAR-T) therapy and bispecific antibodies (BsAbs) have revolutionized the treatment of hematologic malignancies, offering new options for relapsed or refractory cases. However, these therapies carry risks of early complications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and delayed issues like graft-versus-host disease (GVHD), infections, and secondary cancers. Effective management requires early diagnosis using advanced biomarkers and imaging, along with prompt interventions involving immunosuppressants, corticosteroids, and cytokine inhibitors. A multidisciplinary approach is essential, integrating hematologists, oncologists, and infectious disease specialists, with emerging strategies like targeted biologics and personalized medicine showing promise in balancing efficacy with toxicity management. Ongoing research is critical to refine diagnostics and treatments, ensuring that these therapies not only extend survival but also improve patients’ quality of life. This review provides critical insights for healthcare professionals to quickly recognize and treat complications of CAR-T and BsAbs therapies. By focusing on early detection through biomarkers and imaging and outlining timely therapeutic interventions, it aims to equip the multidisciplinary care team with the knowledge necessary to manage the challenges of these advanced treatments effectively, ultimately optimizing patient outcomes.
嵌合抗原受体T细胞（CAR-T）疗法与双特异性抗体（BsAbs）已彻底改变了血液系统恶性肿瘤的治疗格局，为复发或难治性病例提供了新的选择。然而，这些疗法存在早期并发症风险，如细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS），以及移植物抗宿主病（GVHD）、感染和继发性癌症等远期问题。有效管理需要借助先进的生物标志物和影像学技术进行早期诊断，并及时采取免疫抑制剂、皮质类固醇和细胞因子抑制剂等干预措施。多学科协作模式至关重要，需整合血液科、肿瘤科及感染病学专家；新兴策略如靶向生物制剂和个体化医疗在平衡疗效与毒性管理方面展现出潜力。持续研究对优化诊断和治疗方案至关重要，以确保这些疗法不仅能延长生存期，还能改善患者的生活质量。本综述为医疗专业人员快速识别和处理CAR-T及BsAbs疗法并发症提供了关键见解。通过聚焦基于生物标志物与影像学的早期检测，并概述及时的治疗干预措施，旨在为多学科诊疗团队提供有效管理这些先进疗法相关挑战所需的知识，最终优化患者的治疗结局。
肿瘤(癌症)患者之家